{"id":"W2034693832","doi":"10.1016/j.clbc.2011.04.001","title":"Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group","year":2011,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Bevacizumab; Capecitabine; Breast cancer; Mucositis; Internal medicine; Oncology; Cyclophosphamide; Chemotherapy; Metastatic breast cancer; Regimen; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00141006,0.001347894,0.002242643,0.000684187,0.0004290876,0.001012765,0.001006658,0.001017926,0.003345772],"category_scores_gemma":[0.001072443,0.0006724593,0.0009674306,0.0007484055,0.0009398284,0.001109065,0.0004222405,0.003082099,0.000756008],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001293471,"about_ca_system_score_gemma":0.001844151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00303588,"about_ca_topic_score_gemma":0.01182598,"domain_scores_codex":[0.9995626,0.0001571744,0.00002450718,0.0001053331,0.00004922222,0.0001012089],"domain_scores_gemma":[0.9994125,0.0001025046,0.00009569165,0.0000507041,0.000027168,0.0003114893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7390078,0.05926314,0.004155596,0.0007370987,0.0015632,0.0001274558,0.0002787088,0.005078478,0.02258904,0.000617925,0.003284109,0.1632975],"study_design_scores_gemma":[0.6299278,0.3514709,0.008540381,0.00006333165,0.0006133928,0.0001979927,0.00009027411,0.002692719,0.00300188,0.0003902912,0.002962912,0.00004820187],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930166,0.00219034,0.0004628588,0.0005130709,0.0002599432,0.001196377,0.0003390137,0.00008487905,0.001936907],"genre_scores_gemma":[0.9899598,0.002362551,0.002107713,0.0005322781,0.0001790263,0.00117865,0.00095005,0.00003472342,0.002695106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003345772,"threshold_uncertainty_score":0.01119268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07746102873287435,"score_gpt":0.4472544011442907,"score_spread":0.3697933724114163,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}